Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ASA404: Phase II data

Data from 31 previously untreated NSCLC patients in an open-label international Phase II trial showed that ASA404 plus

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE